Possia

RSS

ticagrelor

Withdrawn
This medicine is now withdrawn from use in the European Union.

Overview

The marketing authorisation for Possia has been withdrawn at the request of the marketing-authorisation holder.

This EPAR was last updated on 22/04/2013

Authorisation details

Product details
Name
Possia
Agency product number
EMEA/H/C/002303
Active substance
ticagrelor
International non-proprietary name (INN) or common name
ticagrelor
Therapeutic area (MeSH)
  • Peripheral Vascular Diseases
  • Acute Coronary Syndrome
Anatomical therapeutic chemical (ATC) code
B01AC24
Publication details
Marketing-authorisation holder
AstraZeneca AB
Revision
2
Date of issue of marketing authorisation valid throughout the European Union
03/12/2010
Contact address
Gärtunavägen
151 85 Södertälje
Sweden

Product information

24/10/2012 Possia - EMEA/H/C/002303 - WS/0292

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Antithrombotic agents

Therapeutic indication

Possia, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non-ST-elevation myocardial infarction [NSTEMI] or ST-elevation myocardial infarction [STEMI]); including patients managed medically, and those who are managed with percutaneous coronary intervention (PCI) or coronary artery by-pass grafting (CABG).

Assessment history

How useful was this page?

Add your rating
Average
1 rating